In this 2014 interview, David Ho, Chairman and Managing Director of the pharmaceuticals firm Hovid Berhad, discusses global M&A fever in Big Pharma, offers an update on its latest quarterly earnings, its product mix, ongoing industry drivers and challenges and the importance of its ongoing R&D efforts such as its Tocotrienol drug.

See omnystudio.com/listener for privacy information.